1. Home >
  2. M&A >
  3. Venture >
  4. United States >
  5. New Mexico >
  6. Anzu Partners Invests In BioFlyte

Investment Summary

Anzu Partners Invests In BioFlyte

On June 9, 2020, growth capital firm Anzu Partners invested in life science company BioFlyte

Investment Highlights
  • This is Anzu Partners’ 6th transaction in the Life Science sector.
  • This is Anzu Partners’ 16th transaction in the United States.
  • This is Anzu Partners’ 2nd transaction in New Mexico.

Investment Summary
Date 2020-06-09
Target BioFlyte
Sector Life Science
Investor(s) Anzu Partners
Deal Type Venture

Target

BioFlyte

Albuquerque, New Mexico, United States
BioFlyte is a biodefense and microbial identification company that is commercializing a revolutionary new class of fieldable biological threat collection, detection, and identification solutions. BioFlyte is based in Albuquerque, New Mexico.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Anzu Partners

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 2014
PE ASSETS 1.0B USD
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Anzu Partners is a venture capital and private equity firm that looks to develop and commercialize technological advancements in manufacturing, materials, monitoring/measurement, and modeling. This includes 3D printing, robotics, nanotechnology, composites, sensors, AI, and analytics. Anzu Partners was formed in 2014 and is headquartered in Boston, Massachusetts.

DEAL STATS #
Overall 18 of 36
Sector: Life Science M&A 6 of 11
Type: Venture M&A Deals 18 of 32
State: New Mexico M&A 2 of 2
Country: United States M&A 16 of 30
Year: 2020 M&A 4 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-09 Bioskryb

Durham, North Carolina, United States

Bioskryb is a developer of genomic amplification technologies that deliver unprecedented coverage and fidelity for various gene sequencing applications. Bioskryb was founded in 2018 and is based in Durham, North Carolina.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-07-01 InterVenn Biosciences

South San Francisco, California, United States

InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. InterVenn Biosciences was founded in 2017 and is based in South San Francisco, California.

Buy -
Mergr

Solution for

Product

Company

Legal